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adenocarcinoma (AC) or squamous cell 
carcinoma (SCC) by standard histopath-
ologic methods.” In fact, adding a new 
diagnostic tool to the classical diagnostic 
tool might improve the diagnostic ability. 
Focusing on the use of microRNAassays, 
there are still left concern and questions 
on the cost effectiveness, availability, and 
complexity of the tests. These points have 
to be further discussed. Focusing on MiR-
205 MicroRNA, its diagnostic value for 
differentiating between AC and SCC is 
still controversial. Some previous reports 
showed limitation of its ability to diag-
nose SCC.2 Also, the MiR-205 can also 
increase in the case with severe inflam-
mation and benign tumor.3 The possibility 
of false-positive because of noncancerous 
lesion has to be further studied.
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Surin Rajabhat University
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In Response:
We thank Dr. Wiwanitkit for 
his comments on our study.1 The 
microRNA-based assay described in it 
requires the quantification of only four 
RNAs (miR-21, miR-205, and miR-375, 
and RNU6B). As already noted by us in 
the publication, this can be conveniently 
done in any laboratory with a quantita-
tive polymerase chain reaction machine, 
with time and material costs similar to 
those for immunohistochemistry-based 
diagnosis of non–small-cell lung can-
cer histology. However, the suitability 
of the assay for biospecimens with less 
than 90% tumor content has not been 
assessed by us. In our study, microdis-
section of tumor-containing regions of 
biopsied material was performed for 
76% of biopsies to have ≥90% tumor 
content in the specimens that were used 
for RNA extraction for the microRNA-
based assay.
The studies on the association 
of miR-205 with severe inflammation 
and benign tumor and the lack of a dif-
ferential expression of this microRNA 
between normal and tumor tissues, 
which Dr. Wiwanitkit refers to, con-
cern oral cancer and not cancer of the 
lung. In case of the latter, a significantly 
higher expression of miR-205 in lung 
squamous cell carcinoma tissue com-
pared with normal lung, or lung tissue 
with adenocarcinoma or benign dis-
eases has been noted by many2–5 and in 
Figure 1 of our article.1
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In Response:
We would like to thank Dr. Tapias 
and Dr. Lanuti for their comments on 
our recent article reporting on a mul-
ticenter cohort of 68 patients with 
solitary fibrous tumors of the pleura 
(SFTP), who were analyzed for the 
complete course of the disease in a 
routine practice setting.1 We acknowl-
edge that our recurrence rate of 30% 
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in nonmetastatic disease was higher 
than that previously reported in surgi-
cal series, including that by Tapias et 
al.2 (14%). We hypothesize this may be 
related to (1) a more limited enrollment 
period (12 years from 2000 to 2012, 
versus 33 years from 1977 to 2010 
in the Tapias series) together with (2) 
a prolonged median follow-up of 13 
years and (3) the recruitment of cases 
from medical oncology services, at 
an advanced stage of the disease then 
requiring chemotherapy treatment.1 We 
agree that incomplete resection may 
have contributed to this higher recur-
rence rate, as five patients—four stage 
II tumors, one stage III tumor—had R1 
resection, and two patients—both stage 
III—had R2 resection. We believe this 
reflects routine practice, as other sur-
gical series similarly reported incom-
plete resection to occur in 7% to 11% 
of malignant SFTP.3
On the basis of their series of 59 
patients, Tapias et al. propose a scoring 
system to predict SFTP recurrences; 
four of the six variables of this scor-
ing are actually common with that of 
the England/de Perrot staging, includ-
ing structure, mitotic activity, cellular-
ity, and presence of necrosis.2 Of note, 
Tapias et al. did not applied the de 
Perrot staging to their cases, whereas 
they stated that scoring was a superior 
predictor of recurrence.
Comparing our cohort with this 
series, scores had the following distri-
bution: 0 in 15% versus 42% patients, 
1 in 13% versus 19%, 2 in 28% versus 
19%, 3 in 19% versus 12%, 4 in 7% 
versus 5%, 5 in 9% versus 3%, and 
6 points in 9% versus 0%. Scoring, 
although correlating with the de Perrot 
stage (p < 0.001), was also a significant 
predictor of recurrence-free survival 
(p = 0.007): 3-year, 5-year, 10-year, and 
15-year recurrence-free survival rates 
were 40%, 31%, 25%, and 25%, respec-
tively, for a score ≥3, and 88%, 70%, 
58%, and 58%, respectively, for a score 
<3. These figures are far lower than that 
reported in the original series by Tapias 
et al.—80%, 69%, 23%, and 23% for a 
score ≥3 and 100% for a score of <3—
and in a more recent validation cohort.5 
This reflects the higher aggressiveness 
of our cases that would be even more 
appreciated using the proposed 6-class 
score, which may be even more relevant 
for advanced malignant cases. Whether 
these analyses are relevant to drive peri-
operative management still remains to 
be determined, especially because the 
efficacy of adjuvant treatment is lim-
ited, as highlighted in our cohort.
Ultimately, such major differ-
ences between reported series of TFSPs 
emphasize the need for multicenter col-
laboration to develop prospective obser-
vational cohorts of consecutive patients, 
what remains challenging given the wide 
range of aggressiveness of the disease, 
the long-term survival of patients, and 
the multidisciplinary management from 
initial presentation to recurrent disease.
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